Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 2465 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Fabry Disease | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Fabry disease (MIM 301500) is an X-linked inborn error of glycosphingolipid catabolism. It is caused by inactivating mutations in the GLA gene that encodes a lysosomal enzyme, alpha-galactosidase A. As a result of deficient enzyme activity, neutral glycosphingolipids with terminal %u03B1-galactosyl residues, mainly globotriaosylceramide, accumulate within lysosomes. Typical clinical findings include angiokeratomas, periodic crises of severe pain in the extremities, proteinuria, kidney failure, cardiomyopathy, arrhythmia, abdominal pain, hypohidrosis, transient ischemic attacks, strokes, and corneal and lenticular opacities. The age of onset varies from childhood to adolecense. Classical Fabry disease is typically seen in affected hemizygous males with no enzyme activity. Heterozygous females usually present with a milder phenotype. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| GLA | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Metabolic and Endocrine | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.